Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Desipramine can predict a clinical response in bowel disorders

Blood levels of Desipramine are associated with a clinical response in functional bowel disorders, however, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response, reports the latest issue of American Journal of Gastroenterology

News image

fiogf49gjkf04

As shown in the per protocol analysis of a recent randomized, controlled trial, when tolerated, Desipramine is effective over placebo in treating moderate-to-severe functional bowel disorders.

Clinical experience suggests that the benefit from tricyclic antidepressants in functional bowel disorders can be achieved at doses lower than those used to treat major depression.

Within psychiatry, when using higher dosage of tricyclic antidepressants, plasma levels can be used to adjust daily dosage to optimize a treatment response.

However, in functional bowel disorders, it is not known whether plasma levels at the lower dosage are similarly related to a clinical response.

Dr Halpert and colleagues from Canada determined whether Desipramine blood levels or dose taken can predict a clinical response in treating functional bowel disorders.

The researchers included 431 patients with functional bowel disorder that were part of a study of 12 weeks of antidepressant and psychological treatment at the University of North Carolina and the University of Toronto.

There was a modest correlation between mean Desipramine dose and Desipramine blood level at week 6
American Journal of Gastroenterology

The research team studied those participants who completed treatment (per protocol analysis) taking Desipramine (N = 97, dose 50,150 mg/day) or pill placebo (N = 5,513 pills/day).

The primary outcome measure was defined by the investigators as a composite score (Satisfaction with Treatment, McGill Pain Questionnaire, Global Well-being, and Irritable Bowel Syndrome-Quality of Life).

The composite score was correlated with Desipramine plasma levels at week 6, and the number of pills taken over the duration of the 12 week treatment period.

In addition, the reasearchers also compared Desipramine dose with Desipramine plasma levels.

The team reported a modest correlation between mean Desipramine dose at weeks 5 and 6 and Desipramine blood level at week 6.

However, the research team noted no significant correlations between the composite score either with Desipramine dose or with Desipramine blood levels.

Dr Halpert concludes, “Detectible blood levels of Desipramine are associated with a clinical response in functional bowel disorders.”

“However, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response."

American Journal of Gastroenterology 2005: 100(3): 664
14 March 2005

Go to top of page Email this page Email this page to a colleague

 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 11 May 2018 
Depressive symptoms in IBD youth
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
PPI use and cognitive decline
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Fecal incontinence and quality of life in IBD
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us